Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by Leerink Partnrs

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by Leerink Partnrs from a “hold” rating to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

A number of other research firms have also commented on AGIO. Bank of America lowered their price objective on shares of Agios Pharmaceuticals from $54.00 to $32.00 and set a “buy” rating on the stock in a research note on Thursday. Zacks Research raised Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 4th. Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. HC Wainwright cut their price target on shares of Agios Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating for the company in a report on Thursday. Finally, Scotiabank lowered their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a research note on Monday, July 28th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.67.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $24.57 on Thursday. The business has a 50 day simple moving average of $40.14 and a 200 day simple moving average of $36.82. The firm has a market capitalization of $1.43 billion, a P/E ratio of -3.51 and a beta of 0.89. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $62.45.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, beating the consensus estimate of ($1.93) by $0.15. The company had revenue of $12.90 million for the quarter, compared to analyst estimates of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. Agios Pharmaceuticals’s revenue was up 43.3% compared to the same quarter last year. During the same quarter last year, the business earned $16.22 earnings per share. Research analysts anticipate that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Theodore James Jr. Washburn sold 8,546 shares of the business’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $36.87, for a total transaction of $315,091.02. Following the completion of the transaction, the insider owned 868 shares of the company’s stock, valued at $32,003.16. The trade was a 90.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sarah Gheuens sold 3,302 shares of the business’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $43.92, for a total value of $145,023.84. Following the transaction, the insider directly owned 61,727 shares of the company’s stock, valued at $2,711,049.84. This represents a 5.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 16,099 shares of company stock valued at $620,092. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Bellevue Group AG lifted its position in shares of Agios Pharmaceuticals by 3.5% in the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock worth $149,110,000 after acquiring an additional 124,586 shares during the period. Erste Asset Management GmbH boosted its stake in Agios Pharmaceuticals by 18.8% in the 3rd quarter. Erste Asset Management GmbH now owns 2,764,900 shares of the biopharmaceutical company’s stock valued at $108,578,000 after buying an additional 438,411 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after acquiring an additional 2,049,287 shares during the period. Commodore Capital LP grew its holdings in shares of Agios Pharmaceuticals by 0.6% in the 3rd quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock worth $93,859,000 after purchasing an additional 13,287 shares during the last quarter. Finally, TCG Crossover Management LLC increased its position in shares of Agios Pharmaceuticals by 105.2% during the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after purchasing an additional 733,038 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.